NCT04971226 2026-03-10A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNovartisPhase 3 Active not recruiting406 enrolled 18 charts 1 FDA
NCT02081378 2024-03-18A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLNovartisPhase 1 Completed326 enrolled 1 FDA
NCT02130557 2021-05-18A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaPfizerPhase 3 Completed536 enrolled 24 charts 1 FDA